Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 967

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 967
---
, each of which shall constitute an original, but all of which shall constitute one agreement. This Amendment shall become effective upon delivery to each party of an executed counterpart or the earlier delivery to each party of original, photocopied, or electronically transmitted signature pages that together (but need not individually) bear the signatures of all other parties.

<div align='center'>[The remainder of this page is intentionally left blank; signature pages to follow]

A-2-4</div>

IN WITNESS WHEREOF the parties hereto have caused this Amendment to be duly executed as of the day and year first written above.

| DENALI CAPITAL ACQUISITION CORP. |     |                                 |
| By:                              |     | /s/ Lei Huang                   |
|                                  |     | Name: Lei Huang                 |
|                                  |     | Title:  Chief Executive Officer |
| DENALI MERGER SUB INC.           |     |                                 |
| By:                              |     | /s/ Peter Xu                    |
|                                  |     | Name: Peter Xu                  |
|                                  |     | Title:  President               |
| SEMNUR PHARMACEUTICALS, INC.     |     |                                 |
| By:                              |     | /s/ Jaisim Shah                 |
|                                  |     | Name: Jaisim Shah               |
|                                  |     | Title:  Chief Executive Officer |

A-2-5

#### Annex A-3
<div align='center'>**AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER**</div>

THIS AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of July 22, 2025, is made and entered into by and among Denali Capital Acquisition Corp., a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, “Parent”), Denali Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (the “Merger Sub” and together with Parent, collectively, the “Parent Parties”), and Semnur Pharmaceuticals, Inc., a Delaware corporation (the “Company”).

WHEREAS, the Parent Parties and the Company have entered into an Agreement and Plan of Merger, dated as of August 30, 2024 (as amended, restated, supplemented or otherwise modified from time to time, including pursuant to that certain Amendment No.